Home
Home

Otsuka

Otsuka's tolvaptan gets priority review at FDA

Otsuka's tolvaptan gets priority review at FDA
Pharma Times, UK

Firm ranks top 5 biotech deals in evolving pharma R&D landscape

Firm ranks top 5 biotech deals in evolving pharma R&D landscape
Fierce Biotech

Alzheimer's Drug Race Heats Up With Lundbeck Deal

Alzheimer's Drug Race Heats Up With Lundbeck Deal
Investors.com

Otsuka to Pay Lundbeck $825 Million for Alzheimer’s Drug

Otsuka to Pay Lundbeck $825 Million for Alzheimer’s Drug
Bloomberg

Otsuka, Lundbeck Win Approval for Monthly Abilify Shot

Otsuka, Lundbeck Win Approval for Monthly Abilify Shot
Bloomberg

FDA warns of liver injury risk associated with hyponatremia drug

FDA warns of liver injury risk associated with hyponatremia drug
Healio

Otsuka Can Block Generic Abilify as Court Rejects Appeal

Otsuka Can Block Generic Abilify as Court Rejects Appeal
Bloomberg

It's Hard to Make Money When FDA Approvals Are Priced In

It's Hard to Make Money When FDA Approvals Are Priced In
Motley Fool

Claris Lifesciences to form JV with Otsuka and Mitsui

Claris Lifesciences to form JV with Otsuka and Mitsui
Equity Bulls

Otsuka's Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Tolvaptan, Meets Primary Endpoint in a Phase III Clinical Trial

Otsuka's Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Tolvaptan, Meets Primary Endpoint in a Phase III Clinical Trial
Business Wire